Last reviewed · How we verify
Vancomycin (POC)
Vancomycin inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, preventing cross-linking and causing cell wall rupture.
Vancomycin inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, preventing cross-linking and causing cell wall rupture. Used for Serious or life-threatening infections caused by susceptible strains of methicillin-resistant Staphylococcus aureus (MRSA), Bacterial endocarditis, Clostridium difficile-associated diarrhea and colitis.
At a glance
| Generic name | Vancomycin (POC) |
|---|---|
| Sponsor | University of Maryland, Baltimore |
| Drug class | Glycopeptide antibiotic |
| Target | D-Ala-D-Ala peptidoglycan precursor |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Vancomycin is a glycopeptide antibiotic that binds to the D-alanyl-D-alanine terminus of peptidoglycan precursors in bacterial cell walls, blocking the cross-linking reactions catalyzed by transpeptidases. This prevents proper cell wall formation and integrity, leading to bacterial cell lysis and death. It is bactericidal and particularly effective against gram-positive organisms.
Approved indications
- Serious or life-threatening infections caused by susceptible strains of methicillin-resistant Staphylococcus aureus (MRSA)
- Bacterial endocarditis
- Clostridium difficile-associated diarrhea and colitis
- Staphylococcal enterocolitis
- Gram-positive bacterial infections in penicillin-allergic patients
Common side effects
- Nephrotoxicity (acute kidney injury)
- Ototoxicity (hearing loss)
- Red man syndrome (flushing, pruritus, erythema)
- Phlebitis at infusion site
- Fever
- Chills
- Nausea and vomiting
Key clinical trials
- Primary Prophylaxis of Clostridioides Difficile Infection With Oral Vancomycin (PHASE2, PHASE3)
- Use of Fidaxomicin Compared to Vancomycin for Decolonization of C. Difficile in Patients With Inflammatory Bowel Disease (PHASE4)
- Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vancomycin (POC) CI brief — competitive landscape report
- Vancomycin (POC) updates RSS · CI watch RSS
- University of Maryland, Baltimore portfolio CI